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ABSTRACT

1

Objective To estimate the prevalence of diagnosed
alpha-1 antitrypsin deficiency (dAATD) in Denmark as of 31
December 2018, and dAATD incidence and mortality from
1 January 2000 to 31 December 2018.
Study design and setting We used the Danish National
Patient Registry to identify patients with dAATD based on
the International Classification of Diseases, 10th Revision
(ICD-10) code E88.0A and the Danish Civil Registration
System (CRS) for population counts and vital status. We
estimated dAATD prevalence, incidence and mortality.
We compared mortality among patients with dAATD and
an age-matched and sex-matched cohort extracted from
the Danish CRS. We conducted a sensitivity analysis to
examine whether coding changes during 2000–2018, from
a general to a more specific ICD-10 code for AATD, and left
truncation affected results appreciably.
Results The prevalence of dAATD was 12.9 (95% CI 11.9 to
13.8) per 100 000 persons. The age distribution was bimodal,
with peaks at ages ≤12 and ≥45 years. The incidence rate
per 100 000 person-years was 0.90 (95% CI 0.85 to 0.96),
again with a bimodal age distribution. Mortality was higher for
patients with dAATD than for the general population (mortality
rate ratio (mRR) 4.7, 95% CI 4.1 to 5.3), especially for children
(mRR 33.8, 95% CI 6.8 to 167.4). The sensitivity analysis
indicated that dAATD prevalence might have been as high as
19.7 per 100 000 persons due to less specific ICD-10 coding
for AATD early in the study period or 21.4 per 100 000 persons
correcting for left truncation.
Conclusion Diagnosed AATD was associated with increased
mortality, especially for children. The finding for children was
based on few deaths and had very wide 95% CIs.
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INTRODUCTION
Trypsin is a proteolytic enzyme produced in
the gastrointestinal system.1 Counterbalancing
trypsin is its inhibitor, alpha-1 antitrypsin (AAT),
predominantly produced in the liver.2 AAT plays
a role as a protector in a variety of physiological
processes throughout the body.
AAT deficiency (AATD) is inherited
through autosomal codominant transmission.
The most severe AAT deficiency results from
Z allele homozygosity. Based on a patient’s
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WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Alpha-1 antitrypsin deficiency (AATD) is known to be

appreciably underdiagnosed and a nationwide study
of diagnosed patients has never been undertaken.
⇒ This is the first national study to estimate diagnosed
AATD (dAATD) prevalence and comparative mortality
by age group.

WHAT THIS STUDY ADDS
⇒ We estimated prevalence in Denmark as of 31

December 2018 to be 12.9 per 100 000 persons
(95% CI 11.9 to 13.8) or, in sensitivity analyses, as
high as 21.4 per 100,000 (95% CI 20.3 to 22.6).
Mortality was elevated compared to the general
population (overall mortality ratio = 4.7, 95% CI 4.1
to 5.3), especially for children (mortality ratio 33.8,
95% CI 6.8 to 167.4).

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ The prevalence of dAATD was much lower than the

estimated genetic prevalence of AATD (1/1600) in
southern Scandinavia, confirming the appreciable
underdiagnosis for this condition. The markedly elevated mortality rate ratio for children has not been
estimated previously and warrants confirmation.

genotype, the combination of alleles, and
their environment, patients express different
phenotypes or observable clinical characteristics.3 AATD primarily affects the lungs and
manifests as emphysema, chronic obstructive
pulmonary disease (COPD) and other respiratory conditions (eg, asthma). In the liver,
disease results from accumulation within the
hepatocytes of unsecreted, abnormal, variant
AAT protein. This accumulation causes cytotoxicity that can manifest early as neonatal
liver disease or in adulthood as progressive
liver disease.2
AATD is largely unrecognised.4 In fact,
previous studies, including one in Denmark,
estimate that less than 25% of those with this
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hereditary condition are diagnosed.5 6 Hence, in general
population studies, it is important to differentiate
genetic AATD from diagnosed AATD (dAATD). Diagnosed AATD includes both symptomatic cases and to a
lesser extent those detected through screening, the latter
showing mortality more in line with general population
rates.7 Because dAATD is rare, its frequency and sequalae
are most efficiently studied with healthcare database
studies, provided the databases are of acceptable quality.
A recent study in Germany using a health insurance database that included approximately 87% of the country’s
population reported the prevalence to be 24 per 100
000 persons.8 Prevalence estimates can vary appreciably
across studies, reflecting variations in country-
specific
prevalence, screening activities, data sources, case definitions and analytical methods, especially the length of
the disease lookback period.9 This study focuses on the
Danish national population and capitalises on the availability of lifelong, high-quality health registry data for all
residents for the last several decades.10 11
Study objectives
The primary objective was to estimate the prevalence of
dAATD in Denmark as of 31 December 2018. We defined
prevalence as the number of patients with dAATD per 100
000 Danish residents, who were alive as of 31 December
2018, regardless of how long ago their AATD diagnosis
was made.
Secondary objectives were to estimate dAATD incidence and all-cause mortality for patients with dAATD
and to compare mortality rates for patients with dAATD
to rates for a general population cohort matched on age
and sex. Finally, we characterised patients with dAATD
with respect to respiratory disease, hepatic disease and
related comorbidities.
METHODS
Cohort development
We conducted this nationwide cohort study in Denmark
covering the study period 1 January 2000–31 December
2018. The Danish National Health Service provides
universal tax-supported healthcare for all Danish residents, guaranteeing free access to general practitioners
and hospitals.11 12 We linked patient data at the individual
level across health and administrative registries using the
unique 10-digit identifier assigned by the Danish Civil
Registration System (CRS) to all residents at birth or on
immigration. The CRS updates vital status and immigration status daily for the entire Danish population.11 13 14
The study population alive at the end of the study period
included 5 819 232 residents, and the cumulative study
population during the study period was 7 339 133 residents.
We used the Danish National Patient Registry (DNPR)
that covers all Danish hospitals to identify patients with
a hospital diagnosis of AATD. The DNPR has recorded
non-psychiatric inpatient hospitalisations since 197715 16
2

and outpatient specialist clinic and emergency room data
since 1995. Hospitalisation records in the DNPR include
one primary and one or more secondary diagnoses, coded
according to the International Classification of Diseases
(ICD), 8th Revision between 1977 and 1994 and and the
10th Revision thereafter. We used primary and secondary
10 code E88.0A from inpatient and
diagnoses of ICD-
outpatient hospital visits to identify patients with dAATD.
This specific ICD-10 code for AATD falls into the category E88.0 (diseases of plasma protein metabolism, not
elsewhere classified), of which AATD is the predominant
disease.
Information on comorbidities obtained from the DNPR
included emphysema, other COPD, asthma, bronchitis,
bronchiectasis, other chronic lower respiratory diseases
and liver disease (see online supplemental table 1 for ICD
codes). We used DNPR records from inpatient and outpatient visits before AATD diagnosis, with a maximum lookback to 1977, to calculate Charlson Comorbidity Index
(CCI) scores (see online supplemental table 2 for the
ICD-10 codes used in the CCI and online supplemental
table 3 for the relevant ICD-8 codes). Previous research
has shown high positive predictive values of ICD-10 codes
in the DNPR for the 19 conditions included in the CCI.17
We used the CRS to construct a general population
comparison cohort. For each patient diagnosed with
AATD, we randomly matched up to 100 persons from the
general population (with replacement) on birth year and
sex.14 During the study period, we extracted data on all-
cause mortality from the CRS for patients with dAATD
and for the general population comparison cohort.
Statistical analysis
We defined the index date for patients with dAATD as
the discharge date of the hospital contact that yielded the
AATD diagnosis. We characterised patients with dAATD
by sex, age and CCI score. At the end of the study period
(31 December 2018), we stratified the number of prevalent patients with dAATD and members of the general
population, by age and sex for the prevalence calculation. We also summarised the number and per cent of
patients with dAATD who had specific comorbidities.
We reported overall prevalence per 100 000 persons
and standardised prevalence by sex, age and timepoints
during the study period (end of 2004, 2009, 2014 and
2018). For standardisation purposes, we used the reference age and sex distributions from the Danish population as of 31 December 2018 or as of the end of 2004,
2009 and 2014.
We computed incidence rates of dAATD per 100 000
person-years overall and standardised by sex, age and
calendar timepoints during the 2000–2018 study period.
We used person-years from the general Danish population during the period 1 January 2000–31 December
2018 as the reference for standardisation.
We calculated crude all-cause mortality rates for patients
with dAATD and for members of the age-matched and
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sex-
matched comparison cohort per 100 000 person-
years overall and by sex, age group and calendar time
period. We counted person-
years after the dAATD
patients’ discharge dates for individuals in the matched
comparison cohort, both to mimic the counting of
person-years after diagnosis in the dAATD cohort and
to avoid immortal time bias. Our use of R to 1 (up to
100) matching of persons from the general population to
individual patients with dAATD provides for a descriptive
comparison with comparability on age and sex. However,
mortality rates are not comparable for unmatched
subgroups due to non-comparability on age and/or sex.
We calculated 95% CIs for the prevalence ratio and
for incidence rates using the normal approximation of
the binomial or Poisson distributions, respectively. When
the number of events was too small to apply the normal
approximation (eg, when there were few cases in a young
age group), we calculated exact Poisson 95% CIs.18 We
applied the approximate Wald method to estimate the
95% CIs for mortality rate ratios (mRR) between patients
with dAATD and the general population comparison
cohort.19
In a sensitivity analysis, we examined whether dAATD
cases might have been coded to E88.0, which includes
E88.0A and other rarer disorders. E88.0 was used to identify patients with dAATD in the recent German study.7
We looked for indications of possible changes in AATD
coding practices during the study period. We also evaluated the use of the code E88.0 from 1994 to 1999 to assess
cases possibly missed due to left truncation—diagnoses
before the start of the study period for those who survive
for all or part of the study period. We then recalculated
prevalence at the end of 2018, incorporating our assessment of the number of patients with dAATD using the
more general category code E88.0.
Patient and public involvement
This study used information from the registries cited
above. No patients were involved in setting up the
research question or the outcome measures, nor were
they involved in developing plans for design or implementation of the study. No patients were asked to advise
on interpretation of results or writing of the manuscript.
RESULTS
Table 1 presents sex and age distributions for the Danish
population and surviving patients with AATD as of 31
December 2018 end-of-study date. Females predominate
slightly in the Danish population (as in most developed
countries), but males were the majority among patients
with dAATD. The age distribution of patients diagnosed
with AATD tended to be older than the age distribution
of the Danish general population.
Diagnosed AATD prevalence per 100 000 persons
was 12.9 (95% CI 11.9 to 13.8) as of 31 December 2018
(table 2). Prevalence was 23% higher for males than for
females. Prevalence showed a bimodal distribution by age

Table 1 Age and sex of the Danish population and patients
with dAATD as of 31 December 2018
Danish population

Patients with dAATD

N

%

N

%

Total

5 819 388

100.0

749

100.0

Females

2 922 867

50.2

337

45.0

Males

2 896 521

49.8

412

55.0

 ≤12

823 126

14.1

84

11.2

 13–18

408 755

7.0

26

3.5

 19–24

461 023

7.9

25

3.3

 25–34

748 530

12.9

40

5.3

 35–44

708 488

12.2

85

11.3

 45–54

812 438

14.0

137

18.3

 55–64

720 665

12.4

149

19.9

 ≥65

1 136 363

19.5

203

27.1

Age (years)

dAATD, diagnosed alpha-1 antitrypsin deficiency.

with a slight peak for those ≤12 years of age and a more
pronounced relative higher range of prevalences for
those ≥35 years of age. Prevalence per 100 000 persons
increased during the study period from 1.1 at the end of
2004 to 12.9 at the end of 2018.
Diagnosed AATD incidence was 0.90 (95% CI 0.85 to
0.96) per 100 000 person-years (table 3). Incidence was
21% higher for males than for females. Incidence showed
a bimodal age distribution similar to that seen for prevalence. Incidence rates increased during the study period.
Follow-up was 99.1% complete for patients with dAATD
at the end of the study period. Seven hundred and forty-
nine patients with dAATD were alive as of the end of 2018
and 280 died or emigrated prior to the end of the study
period for a total of 1029 patients diagnosed during the
2000–2018 study period. In table 4, we detail mortality
rates and mRRs for patients with dAATD compared with a
matched Danish general population cohort. Overall, the
mRR was 4.7 (95% CI 4.1 to 5.3). The mRR for females
with dAATD was 5.3 (95% CI 4.5 to 6.3) compared with
the matched female general population comparison
cohort, while the mRR for males with dAATD was 4.2
(95% CI 3.5 to 4.9) compared with the matched male
general population cohort.
Comparative mortality for patients with dAATD by age
group was markedly higher for younger than for older
age groups compared with their age-matched and sex-
matched general population peers. For example, the mRR
was 33.8 (95% CI 6.8 to 167.4) for children and adolescents with dAATD, the age groups for which mortality is
the lowest in the general population. The wide 95% CIs
indicate that this result was based on a small number of
deaths. In contrast, the mRR was 4.2 (95% CI 3.6 to 5.0)
in the oldest age group (≥ 65 years), the age group for
which mortality is the highest in the general population.

Acquavella J, et al. BMJ Open Resp Res 2022;9:e001281. doi:10.1136/bmjresp-2022-001281

3

BMJ Open Resp Res: first published as 10.1136/bmjresp-2022-001281 on 22 December 2022. Downloaded from http://bmjopenrespres.bmj.com/ on January 4, 2023 at Thomas Jefferson
University. Protected by copyright.

Open access

Table 2 Prevalence of dAATD per 100 000 persons as of 31 December 2018
Population as of 31
December 2018

cases (N)

Prevalence

95% CI

Overall
By Sex*

5 819 388

749

12.9

11.9 to 13.8

 Females

2 922 867

337

11.4

10.2 to 12.6

 Males

2 896 521

412

14.3

12.9 to 15.7

 ≤12

823 126

84

10.1

8.0 to 12.3

 13–18

408 755

26

6.4

3.9 to 8.8

 19–24

461 023

25

5.4

3.3 to 7.5

 25–34

748 530

40

5.3

3.7 to 7.0

 35–44

708 488

85

12.0

9.4 to 14.5

 45–54

812 438

137

16.8

14.0 to 19.6

 55–64

720 665

149

20.7

17.4 to 24.0

 ≥65

1 136 363

203

17.9

15.4 to 20.3

 2004

5 489 869

63

1.1

0.8 to 1.4

 2009

5 617 289

220

4.0

3.4 to 4.5

 2014
 2018

5 728 373
5 819 388

468
749

8.2
12.9

7.5 to 8.9
11.9 to 13.8

By Age (years)†

By end of year†‡

*Adjusted to the population age distribution as of 31 December 2018.
†Adjusted to the population sex distribution as of 31 December 2018.
‡Adjusted to the age and sex distribution as of 31 December 2018.
AATD, alpha-1 antitrypsin deficiency; dAATD, diagnosed alpha-1 antitrypsin deficiency.

The mRR for patients with dAATD versus the general
population declined markedly over the study period,
from 17.8 (95% CI 11.0 to 28.8) in 2000–2004 to 7.6 (95%
CI 5.8 to 9.9) in 2005–2009, to 5.1 (95% CI 4.2 to 6.2) in
2010–2014, and ultimately to 3.2 (95% CI 2.6 to 3.9) in
2015–2018. Note that the rates during the different time
intervals are based on different age and sex distributions
and are not exactly comparable. Nonetheless, the general
trend of declining mortality for patients with dAATD is
unmistakable and likely fairly robust to differences in the
age and sex distributions from the beginning to the end
of the study period.
In table 5, we characterise the 1029 patients with AATD
diagnosed any time during the 2000–2018 study period
with respect to lung and liver conditions. Approximately
66% had a diagnosis of chronic respiratory disease. The
most frequent diagnoses were emphysema in 34% of
patients and asthma in 19% of patients. We found that
10.8% of patients had a liver disease diagnosis and 5.2%
of patients had diagnoses of both lung and liver disease.
In the sensitivity analysis, we observed that the ICD-10
code E88.0A was infrequent early in the study period and
largely replaced E88.0 by the end of our study period,
indicating the predominance of AATD in the E88.0
category and a near complete shift to the more specific
E88.0A ICD-10 code for AATD. Had we used ICD-10 E88.0
in addition to E88.0A during the entire study period, we
4

would have identified 1148 patients as diagnosed with
AATD and alive as of the end of the study period instead
of 749 patients and prevalence would have been 19.7
(95% CI 18.6 to 20.9) per 100 000 persons instead of 12.9
(95% CI 11.9 to 13.8) per 100 000 persons. Regarding
left truncation, we identified 96 patients with an E88.0
code during the 1994–1999 interval and no subsequent
E88.0A or E88.0 codes who survived for all of our study
period. Had they been included in the sensitivity analysis, the prevalence would have been 21.4 (95% CI 20.3
to 22.6) per 100 000 persons.
DISCUSSION
This cohort study of dAATD prevalence, incidence and
mortality based on ICD-10 codes in the DNPR and population estimates from the CRS is the first to be based on
an entire national population with universal medical
coverage and conducted over an extended time period.
The Danish data systems we used are optimum for the
study of population prevalence for diagnosed conditions
due to their complete coverage of the resident population and extended time period of coverage. Our estimate of Danish dAATD prevalence as of 31 December
2018 based on ICD-10 code E88.0A was 12.9 per 100 000
persons. We found that diagnosed prevalence increased
during the study period presumably due to increased
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Table 3 Incidence rates of dAATD per 100 000 person-
years

Incidence

Standardised
incidence rate/100
000 person-years 95% CI

Overall
By Sex*

0.90

 Females

0.81

 Males

0.98

Table 4 Mortality rates per 100 000 person-years among
patients with dAATD and a matched Danish general
population comparison cohort and mortality rate ratios

Mortality

AATD
Patients
mortality
rate/ 100
000 pyrs

Danish
population
mortality
rate/100 000 Mortality rate ratio
pyrs
(95% CI)

0.74 to 0.89

Overall

5444

1169

4.7 (4.1 to 5.3)

0.9 to 1.06

By sex
 Females

5774

1091

5.3 (4.5 to 6.3)

 Males

5159

1239

4.2 (3.5 to 4.9)

 ≤18*

273

8

33.8 (6.8 to 167.4)

 19–34*

343

39

8.8 (1.1 to 68.4)

 35–44

2628

134

19.7 (11.1 to 34.8)

 45–54

3341

323

10.3 (7.2 to 14.8)

 55–64

6210

806

7.7 (6.1 to 9.8)

 ≥65

11 775

2780

4.2 (3.6 to 5.0)

0.85 to 0.96

By Age (years)†
 ≤12

0.64

0.53 to 0.76

 13–18

0.26

0.16 to 0.36

 19–24

0.19

0.10 to 0.27

 25–34

0.40

0.30 to 0.50

 35–44

0.91

0.76 to 1.06

 45–54

1.34

1.16 to 1.53

 55–64

1.74

1.52 to 1.96

 ≥65

1.26

1.10 to 1.43

 2000–2004

16 439

923

17.8 (11.0 to 28.8)

 2000–2004

0.27

0.21 to 0.33

 2005–2009

8140

1076

7.6 (5.8 to 9.9)

 2005–2009

0.71

0.62 to 0.81

 2010–2014

5971

1176

5.1 (4.2 to 6.2)

 2010–2014
 2015–2018

1.16
1.59

1.04 to 1.28
1.43 to 1.75

 2015–2018

3833

1201

3.2 (2.6 to 3.9)

By time period†‡

*Adjusted to the population age distribution during 1 January
2000–31 December 2018.
†Adjusted to the population sex distribution during 1 January
2000–31 December 2018.
‡Adjusted to the population age and sex distribution during 1
January 2000–31 December 2018.
dAATD, diagnosed alpha-1 antitrypsin deficiency.

medical awareness; diagnosed prevalence was higher for
men than women, presumably due to an increased likelihood of diagnosis as AATD is not sex linked and higher
rates of smoking for men are likely to accelerate lung
and other disease manifestations5; and the age distribution was bimodal—higher for those ≤12 years of age
compared with adolescents and young adults and higher
for those ≥45 years of age. Incidence rates followed the
same general patterns.
Evaluation of mortality, compared with an age-matched
and sex-matched general population cohort showed an
overall mRR of 4.7 for patients diagnosed with AATD.
Age-specific mortality ratios were highest in the youngest
age groups, notably with very wide 95% CIs, where general
population mortality is low and lowest for those ≥65 years
of age. This pattern is consistent with the known clinical
course of AATD. Early-onset AATD often is more severe.
Liver disease dominates in early childhood along with
some early cases of emphysema.20 Chronic pulmonary
disease of variable severity tends to occur after age 30.21
The trend of decreasing mRRs for patients with dAATD
over the study period likely can be explained by a combination of factors: increased recognition of less severe

By age (years)

By time period

*Age categories condensed because no deaths occurred among
patients with AATD aged 13–18 years and 25–34 years.
AATD, alpha-1 antitrypsin deficiency; pop, population; pyrs, person
years.

cases in more recent years, improvements in medical
care, and short follow-up for those patients with AATD
recognised late in our study period.
Our estimate of dAATD prevalence in Denmark of 12.9
per 100 000 persons is appreciably lower than the estimated 23.7 per 100 000 persons in the recent report from
Germany.8 Our sensitivity analyses found that there were
observable changes in ICD-10 coding during the study
period from the more general category code E88.0 to
the more specific code E88.0A. Had we used the ICD-10
code E88.0 as in the German study, our estimate of prevalence would have been 19.7 (95% CI 18.6 to 20.9) per
100 000 persons. Correcting for left truncation would
have increased the prevalence to 21.4 (95% CI 20.3 to
22.6) per 100 000 persons. The combined impacts of
the change in ICD-10 coding practices and left truncation were to underestimate prevalence, to identify some
prevalent patients as incident patients for those who had
the E88.0 code initially followed by the E88.0A code,
and to underestimate incidence. Mortality probably was
not affected because mortality rates were unlikely to be
appreciably different for patients with dAATD coded
using E88.0 versus those coded using E88.0A. The most
marked differences in prevalence and incidence would be
in analyses covering the first 10 years of the study period,
when only a small fraction of patients with dAATD were
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Table 5 Characteristics of patients with AATD diagnosed
during the period 1 January 2000–31 December 2018
N

%

Total

1029

100

 Females

476

46.3

 Males

553

53.7

Age (years)
 ≤12

113

11.0

 13–18

25

2.4

 19–24

18

1.7

 25–34

61

5.9

 35–44

143

13.9

 45–54

204

19.8

 55–64

236

22.9

 ≥65

229

22.3

Charlson Comorbidity Index score at Dx date
 0

417

40.5

 1–2

465

45.2

 ≥3

147

14.3

Lung diseases
 No

354

34.4

 Yes

675

65.6

Emphysema
 No

676

65.7

 Yes

353

34.3

Asthma
 No

832

80.9

 Yes

197

19.1

 No

440

42.8

 Yes

589

57.2

Other COPD

disorders. This is consistent with the known predominance of pulmonary manifestations over the lifespan of
patients with AATD.22 23 A small minority of patients had
disorders of both the lung and liver.
We note several important limitations with our analyses
that we enumerate to allow informed interpretation. The
extent of morbidity and mortality is known to depend
on AATD genotype,24 AAT serum levels, environmental
exposures5 and other risk factors (eg, smoking). That
information was not available in the registries used for
our analyses. Second, screening can affect prevalence by
identifying asymptomatic cases. Screening is reported
to be increasing in the UK and Spain.25 26 In Denmark,
according to national guidelines, first-degree relatives of
patients with AATD are offered testing, but it is not known
what proportion of these relatives get tested.27 Lastly,
diagnoses in the DNPR are based on ICD codes. Several
classes of coding problems are known to exist including:
variation among coders, errors in coding, lack of codes
for certain data points, limitations in the specificity of
available codes, and errors and variation in the clinical
diagnoses on which the coding is based.28–31 Evaluations
in Germany and Italy found the diagnosis of AATD to
be delayed significantly after initial symptoms (median
7 years and 6 years, respectively) and that there was low
awareness of AATD among non-specialist general physicians.32 This would lead to appreciable underestimation
of prevalence. Indeed, our study and previous studies
provide prevalence estimates well below what would be
predicted by screening studies—approximately 1/1600
in southern Scandinavia.5 6 33 Conversely, diagnoses of
AATD would be expected to have very high specificity
and positive predictive value.

Bronchitis
 No

1011

98.3

 Yes

18

1.7

CONCLUSIONS
In conclusion, our estimates of incidence and prevalence
show dAATD to be rare with a prevalence of approximately 12.9–21.4 per 100 000 persons using the specific
versus the more general category ICD code, respectively,
and correcting for left truncation. Using an estimate of
the prevalence of genetic AATD variants for Scandinavia
of 1/1600, our prevalence estimate of dAATD is perhaps
a third or less of the true prevalence of AATD. However,
it likely comprises the vast majority of patients with markedly increased morbidity and mortality. With that qualification, our analyses indicate that dAATD is associated
with markedly elevated mortality, especially for children,
though the mRR for children is based on few deaths and
has very wide CIs.

Other chronic lower respiratory disease
 No

1021

99.2

 Yes

8

0.8

Bronchiectasis
 No

972

94.5

 Yes

57

5.5

 No

918

89.2

 Yes

111

10.8

Liver disease

Lung and liver disease
 No

975

94.8

 Yes

54

5.2

AATD, alpha-1 antitrypsin deficiency; COPD, chronic obstructive pulmonary disease;
Dx, diagnosis.

coded to the more specific within category ICD code
E88.0A.
Our study showed that AATD sequalae manifest
primarily as lung disorders and, to a lesser extent, liver
6
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Supplementary Table 1. Characteristics of patients with AATD diagnosed during the period
1/1/2000 through 12/31/2018, classified by ICD-10 diagnosis codes

ICD-10 Diagnosis Description

ICD-10 Code

Lung diseases

J40-J47

Bronchitis

J41

Emphysema

J43

Other chronic obstructive pulmonary disease

J 44

Asthma

J45

Bronchiectasis

J47

All other chronic lower respiratory diseases

J46

Liver disease

K70 – K76

Abbreviation: ICD= International Classification of Diseases
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Supplementary Table 2. Conditions included in the Charlson Comorbidity Index, according
to ICD-8 and ICD-10 Codes
Charlson Condition

ICD-8 Code

ICD-10 Code

Myocardial infarction

410

I21, I22, I23

Congestive heart failure

427.09–427.11, 427.19, 428.99,
782.49

I50, I11.0, I13.0, I13.2

Peripheral vascular disease

440-445

I70, I71, I72, I73, I74, I77

Cerebrovascular disease

430-438

I60-I69, G45, G46

Dementia

290.09–290.19, 293.09

F00-F03, F05.1, G30

490–493, 515–518

J40-J47, J60-J67, J68.4, J70.1,
J70.3, J84.1, J92.0, J96.1, J98.2,
J98.3

135.99, 446, 712, 716, 734

M05, M06, M08, M09, M30,
M31, M32, M33, M34, M35,
M36, D86

530.91, 530.98, 531–534

K22.1, K25-K28

571, 573.01, 573.04

B18, K70.0-K70.3, K70.9,
K71, K73, K74, K76.0

Diabetes mellitus

249.00, 249.06, 249.07, 249.09,
250.00, 250.06, 250.07, 250.09

E10.0, E10.1, E10.9, E11.0;
E11.1; E11.9

Diabetes mellitus with
chronic complications

249.01-249.06, 249.08, 250.01250.05, 250.08

E10.2-E10.8, E11.2-E11.8

Hemiplegia

344

G81, G82

Moderate/severe renal
disease

403, 404, 580–584, 590.09,
593.19, 753.10–753.19, 792

I12, I13, N00-N05, N07, N11,
N14, N17-N19, Q61

Any tumor

140-194

C00-C75

Leukemia

204-207

C91-C95

Lymphoma

200-203, 275.59

C81-C85, C88, C90, C96

Moderate/severe liver disease

070.00, 070.02, 070.04, 070.06,
070.08, 573.00, 456.00–456.09

B15.0, B16.0, B16.2, B19.0,
K70.4, K72, K76.6, I85

Metastatic solid tumor

195-199

C76-C80

AIDS

079.83

B21-B24

Chronic pulmonary disease

Connective tissue disease
Ulcer disease
Mild liver disease
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